Literature DB >> 10892914

Pleural tent after upper lobectomy: a prospective randomized study.

A Brunelli1, M Al Refai, M Muti, A Sabbatini, A Fianchini.   

Abstract

BACKGROUND: The aim of the present study was to assess the cost/efficacy of the pleural tent procedure after upper lobectomy.
METHODS: A prospective randomized analysis was performed on 50 patients submitted to upper lobectomy and divided into two groups: group 1 (25 patients) with pleural tent; group 2 (25 patients) without pleural tent.
RESULTS: The univariate comparison between the two groups did not show any significant difference in terms of age, gender, spirometry, smoking history, chronic obstructive pulmonary disease index, side of tumor, arterial oxygen tension, arterial carbon dioxide tension, size and location of tumor, presence of pleural adhesions, length of the stapled parenchyma, and operative time. Pleural tent significantly reduced the days of postoperative air leak (1.2 versus 5.8, p = 0.01), chest tubes (5.4 versus 10.4, p = 0.01), and hospital stay (6.9 versus 10.8, p = 0.01). Moreover, no difference was noted between the two groups in terms of pleural effusion in the first postoperative 48 hours, need of postoperative blood transfusion, and occurrence of other complications.
CONCLUSIONS: Pleural tenting after upper lobectomy is a safe and effective procedure and its routine use is warranted.

Entities:  

Mesh:

Year:  2000        PMID: 10892914     DOI: 10.1016/s0003-4975(00)01166-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Definition of postresectional residual pleural space.

Authors:  Okan Solak; Adnan Sayar; Muzaffer Metin; Akif Turna; Volkan Erdogu; Atilla Pekçolaklar; Atilla Gürses
Journal:  Can J Surg       Date:  2007-02       Impact factor: 2.089

2.  Reverse airflow in certain chest drains may be misinterpreted as prolonged air leakage.

Authors:  Anna Stouby; Kirsten Neckelmann; Peter B Licht
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.